RG
RGRX.US Regenerx Biopharm In
- Market cap
- USD 1.65K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2023.
Is RGRX.US undervalued?
Graham numberThe Graham number of Regenerx Biopharm In cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Regenerx Biopharm In fundamental analysis
No fundamental analysis for Regenerx Biopharm In yet.
Regenerx Biopharm In stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Regenerx Biopharm In
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, develops pharmaceuticals from Thymosin beta 4 (Tß4) for tissue protection, repair, and regeneration. The company is developing RGN-259, a sterile and preservative-free eye drop that has completed Phase 3 clinical trial for the treatment of dry eye syndrome and neurotrophic keratitis. It has strategic partnerships with Lee's Pharmaceutical Group for the development and marketing of Tß4-related products; and HLB T…
Full company profileRegenerx Biopharm In financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Regenerx Biopharm In annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 29.0K | 0.00 | 60.6K | 93.3K | 56.7K | 69.7K | 76.8K | 76.8K | 76.8K | 76.8K | 76.8K |
| Gross Profit | - | -367K | -143K | -144K | -87.3K | -11.4K | 76.8K | - | - | - | - |
| Operating Income | - | -1.56M | -1.71M | -1.67M | -1.44M | -1.32M | -1.26M | -1.29M | -1.33M | -1.40M | -1.22M |
| EBITDA | - | - | - | - | 559K | -1.90M | -1.25M | -1.29M | -1.27M | -1.40M | -1.22M |
| Net Income | - | -2.75M | -5.27M | 229K | 286K | -1.99M | -1.40M | -1.52M | -1.60M | -1.73M | -1.54M |
| EPS | - | - | - | - | 0.00 | -0.02 | -0.01 | -0.01 | -0.01 | -1.20 | -1.07 |
| Balance Sheet | |||||||||||
| Total Assets | 43.0K | 949K | 358K | 862K | 227K | 281K | 712K | 552K | 1.28M | 382K | 187K |
| Total Liabilities | 1.66M | 2.66M | 7.10M | 6.93M | 4.34M | 2.49M | 3.05M | 3.38M | 3.51M | 3.83M | 3.93M |
| Shareholders' Equity | -1.62M | -1.71M | -6.74M | -6.07M | -4.12M | -2.21M | -2.34M | -2.82M | -2.23M | -3.45M | -3.74M |
| Cash & Short-term Investments | 6.00K | 844K | 318K | 769K | 182K | 237K | 640K | 428K | 1.23M | 291K | 102K |
| Cash Flow | |||||||||||
| Operating Cash Flow | - | -1.70M | -525K | -1.07M | -663K | -888K | -1.14M | -1.01M | -990K | -941K | -757K |
| Capital Expenditure | 0.00 | 13.0K | 1.08K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | - | - | - | -663K | -888K | -1.14M | -1.01M | -990K | -941K | -757K |
| Ratios | |||||||||||
| ROA | - | -290.2% | -1,471.3% | 26.6% | 126.2% | -709.3% | -197.3% | -276.1% | -124.3% | -452.0% | -824.8% |
| Net Profit Margin | - | - | -8,695.4% | 245.6% | 505.7% | -2,861.5% | -1,829.4% | -1,984.6% | -2,081.5% | -2,250.4% | -2,007.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Regenerx Biopharm In dividends
Regenerx Biopharm In has not paid dividends in the last 9 fiscal years.
Last stock split: 1:100 on Oct 18, 2023.
Who owns Regenerx Biopharm In
Ownership data of Regenerx Biopharm In is not available yet.
Regenerx Biopharm In company profile
- Company name
- Regenerx Biopharm In
- Ticker
- RGRX.US
- Exchange
- USA Stocks
- Listed since
- Dec 23, 1986
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- December
- Address
- 15245 Shady Grove Road, Rockville, MD, United States, 20850
- Phone
- 301 208 9191
- Website
- regenerx.com
About Regenerx Biopharm In
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, develops pharmaceuticals from Thymosin beta 4 (Tß4) for tissue protection, repair, and regeneration. The company is developing RGN-259, a sterile and preservative-free eye drop that has completed Phase 3 clinical trial for the treatment of dry eye syndrome and neurotrophic keratitis. It has strategic partnerships with Lee's Pharmaceutical Group for the development and marketing of Tß4-related products; and HLB Therapeutics for the development and marketing of RGN-259, and RGN-137 for dermal wound healing. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in December 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.
Regenerx Biopharm In management
2- Dr. Allan L. Goldstein Ph.D.Founder, Chairman, Chief Scientific Officer & Chairman of Scientific Advisor Board · born 1938
- Mr. J. J. FinkelsteinPresident, CEO & Director · born 1952